Additionally, PD-1/TIM-3 co-expression in the tumor microenvironment is linked to poor prognosis and chemoresistance, while tumor mutational burden (TMB) and microsatellite instability (MSI) are established predictive markers for immunotherapy response, though their prevalence in GBC remains low [27]. The gene discussed is HAVCR2; the disease is neoplasm.